Breaking News Instant updates and real-time market news.

ACAD

Acadia

$24.97

-0.69 (-2.69%)

12:44
05/19/19
05/19
12:44
05/19/19
12:44

Acadia presents Phase 2 CLARITY results for Pimavanserin

Acadia Pharmaceuticals presented data from its Phase 2 CLARITY study, which evaluated the efficacy, safety, and tolerability of pimavanserin as an adjunctive treatment for major depressive disorder at the 2019 American Psychiatric Association Annual Meeting. The Phase 2 CLARITY study was a 10-week, randomized, double-blind, placebo-controlled, multi-center, two-stage sequential parallel comparison design study that evaluated the efficacy, safety, and tolerability of pimavanserin. Pimavanserin was administered as an adjunctive treatment in patients with MDD who had an inadequate response to a stable dose of standard antidepressant therapy with either a selective serotonin reuptake inhibitor or a serotonin norepinephrine reuptake inhibitor. The study randomized 207 patients across 27 clinical research centers in the U.S. and was conducted in collaboration with the Massachusetts General Hospital Clinical Trials Network and Institute. In the trial, pimavanserin met the overall primary endpoint of the weighted average results of Stage 1 and Stage 2 by significantly reducing the 17-item Hamilton Depression Rating Scale total score compared to placebo. On the key secondary endpoint, pimavanserin demonstrated statistically significant reductions compared to placebo in the Sheehan Disability Scale score. Positive results were also observed for seven other secondary endpoints, including improvement in daytime sleepiness as measured by the Karolinska Sleepiness Scale and improvement in sexual function as measured by the Massachusetts General Hospital Sexual Functioning Index. On April 25, ACADIA announced it had initiated its Phase 3 CLARITY program for pimavanserin as an adjunctive treatment for MDD. The CLARITY-2 study will be based in the U.S. and has already initiated enrollment and the CLARITY-3 study will be based outside the U.S. and will initiate enrollment in the upcoming months. Both studies are six-week, parallel-designed, randomized, double-blind, placebo-controlled, multi-center studies designed to evaluate the efficacy and safety of pimavanserin as adjunctive treatment in patients with MDD who have an inadequate response to standard antidepressant therapy with either a SSRI or a SNRI.

ACAD Acadia
$24.97

-0.69 (-2.69%)

05/01/19
PIPR
05/01/19
NO CHANGE
Target $35
PIPR
Overweight
Acadia price target raised to $35 from $30 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target on Acadia to $35 and kept her Overweight rating after its better than expected Q1 sales of Nuplazid that was driven by "accelerated growth in new patient starts." The analyst further cites the management's increased FY19 Nuplazid midpoint sales guidance and also sees "significant unrealized value" for the company's dementia related psychosis programs.
02/27/19
PIPR
02/27/19
NO CHANGE
Target $30
PIPR
Overweight
Acadia price target raised to $30 from $25 at Piper Jaffray
Piper Jaffray analyst Danielle Brill raised her price target for Acadia Pharmaceuticals to $30 following the company's Q4 results. The analyst expects Nuplazid' "modest" revenue growth to continue as safety concerns "slowly subside." She also anticipates a beneficial impact to 2019 sales from the ongoing direct-to-consumer campaign. As such, the company's fiscal 2019 guidance of $275M-$300M "appears in line and readily achievable," Brill tells investors in a post-earnings research note. With Acadia beginning two Phase 3 major depressive disorder trials in the first half of 2019, the analyst expects the shares to start reflecting value for the indication as the program continues to advance. She introduced probability-adjusted numbers at a 25% chance of success into her model and keeps an Overweight rating on Acadia.
02/27/19
ADAM
02/27/19
NO CHANGE
Target $27
ADAM
Hold
Canaccord says Acadia shares 'getting interesting,' raises price target to $27
Canaccord analyst Sumant Kulkarni said Acadia reported decent Q4 results, with Nuplazid sales coming in in-line with expectations. The outlook was solid, suggesting the media issues the drug faced are behind it, which is encouraging, said Kulkarni. With that out of the way, the analyst believes the stock is getting more interesting heading into data readouts for the company's dementia and schizophrenia drugs. Kulkarni maintained his Hold rating and raised his price target to $27 from $23 on Acadia shares.
12/10/18
ADAM
12/10/18
INITIATION
Target $23
ADAM
Hold
Acadia initiated with a Hold at Canaccord
Canaccord analyst Sumant Kulkarni initiated Acadia Pharmaceuticals with a Hold rating and $23 price target. In a research note to investors, Kulkarni says that while he believes Acadia is a core holding for investors seeking exposure to central nervous system, or CNS, companies with commercial assets, he believes the risk/reward on the stock is balanced ahead of potential issuance of the company's initial 2019 outlook for Nuplazid in Parkinson's Disease psychosis, or PDP, and views his sales estimate for Nuplazid as "reasonable," though he admits he has low visibility heading into the event.

TODAY'S FREE FLY STORIES

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

21:23
07/22/19
07/22
21:23
07/22/19
21:23
Downgrade
Stifel downgrades Viveve to Hold after trial miss, cuts target to $1 »

Stifel analyst Jonathan…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

21:15
07/22/19
07/22
21:15
07/22/19
21:15
Hot Stocks
Viveve CMRF technology trial did not demonstrate improvement in SUI »

Earlier this evening,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VIVE

Viveve

$0.41

-0.0155 (-3.68%)

21:12
07/22/19
07/22
21:12
07/22/19
21:12
Downgrade
Viveve rating change at Stifel »

Viveve downgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

, UTX

United Technologies

$132.94

0.57 (0.43%)

20:25
07/22/19
07/22
20:25
07/22/19
20:25
Earnings
Notable companies reporting before tomorrow's open »

Notable companies…

KO

Coca-Cola

$51.25

-0.15 (-0.29%)

UTX

United Technologies

$132.94

0.57 (0.43%)

LMT

Lockheed Martin

$357.57

0.675 (0.19%)

KMB

Kimberly-Clark

$134.40

-1.31 (-0.97%)

BIIB

Biogen

$232.46

1.26 (0.54%)

SHW

Sherwin-Williams

$454.62

-1.9 (-0.42%)

TRV

Travelers

$149.95

-0.22 (-0.15%)

PCAR

Paccar

$69.17

-0.16 (-0.23%)

CNC

Centene

$52.19

-0.46 (-0.87%)

SWK

Stanley Black & Decker

$141.45

-2.01 (-1.40%)

FITB

Fifth Third

$27.84

-0.11 (-0.39%)

KEY

KeyCorp

$17.37

-0.08 (-0.46%)

TRU

TransUnion

$74.91

-0.14 (-0.19%)

HAS

Hasbro

$108.54

0.85 (0.79%)

DGX

Quest Diagnostics

$98.07

-1.175 (-1.18%)

LW

Lamb Weston

$67.58

-0.98 (-1.43%)

JBLU

JetBlue

$18.96

0.05 (0.26%)

HOG

Harley-Davidson

$34.25

-0.62 (-1.78%)

MDSO

Medidata

$90.93

0.2 (0.22%)

GPK

Graphic Packaging

$14.27

0.025 (0.18%)

AN

AutoNation

$42.01

-0.045 (-0.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 01

    Aug

  • 01

    Aug

  • 06

    Aug

  • 06

    Aug

  • 08

    Aug

  • 12

    Aug

  • 29

    Aug

  • 09

    Sep

  • 19

    Sep

  • 13

    Nov

ACAD

Acadia

$25.97

0.28 (1.09%)

20:21
07/22/19
07/22
20:21
07/22/19
20:21
Recommendations
Acadia analyst commentary at Piper Jaffray »

Acadia's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Jul

  • 20

    Aug

EFII

Electronics for Imaging

$36.97

(0.00%)

20:12
07/22/19
07/22
20:12
07/22/19
20:12
Hot Stocks
Breaking Hot Stocks news story on Electronics for Imaging »

Electronics for Imaging…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

20:04
07/22/19
07/22
20:04
07/22/19
20:04
Downgrade
Zions Bancorp rating change at Wells Fargo »

Zions Bancorp downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

CADE

Cadence Bancorp

$15.86

-3.75 (-19.12%)

20:03
07/22/19
07/22
20:03
07/22/19
20:03
Downgrade
Cadence Bancorp rating change  »

Cadence Bancorp cut to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 06

    Aug

  • 26

    Aug

  • 23

    Sep

OISHY

Oil Search

$0.00

(0.00%)

19:38
07/22/19
07/22
19:38
07/22/19
19:38
Upgrade
Oil Search rating change at Morgan Stanley »

Oil Search upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

QCOM

Qualcomm

$75.93

0.9 (1.20%)

, INTC

Intel

$51.36

1.1 (2.19%)

19:11
07/22/19
07/22
19:11
07/22/19
19:11
Periodicals
Trump to grant timely licensing decisions for Huawei sales, WSJ reports »

U.S. President Donald…

QCOM

Qualcomm

$75.93

0.9 (1.20%)

INTC

Intel

$51.36

1.1 (2.19%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

MU

Micron

$47.21

1.7 (3.74%)

WDC

Western Digital

$55.32

2.87 (5.47%)

CSCO

Cisco

$57.72

0.34 (0.59%)

AVGO

Broadcom

$296.11

6.06 (2.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

  • 25

    Jul

  • 25

    Jul

  • 31

    Jul

  • 31

    Jul

  • 03

    Aug

  • 08

    Aug

  • 14

    Aug

  • 27

    Oct

LPL

LG Display

$7.45

0.275 (3.83%)

18:51
07/22/19
07/22
18:51
07/22/19
18:51
Periodicals
Breaking Periodicals news story on LG Display »

LG Display to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

F

Ford

$10.02

-0.03 (-0.30%)

18:51
07/22/19
07/22
18:51
07/22/19
18:51
Periodicals
Ford to spend $50M to upgrade Chicago plant for SUVs, Reuters reports »

Ford intends to invest…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Jul

  • 23

    Oct

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

, SNAP

Snap

$14.14

0.12 (0.86%)

18:48
07/22/19
07/22
18:48
07/22/19
18:48
Hot Stocks
Fly Intel: After Hours Movers »

UP AFTER EARNINGS: Brown…

BRO

Brown & Brown

$34.64

-0.11 (-0.32%)

SNAP

Snap

$14.14

0.12 (0.86%)

INTC

Intel

$51.36

1.1 (2.19%)

QCOM

Qualcomm

$75.93

0.9 (1.20%)

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

ZION

Zions Bancorp

$45.16

-0.95 (-2.06%)

CDNS

Cadence Design

$72.68

-0.21 (-0.29%)

SNPS

Synopsys

$135.42

0.41 (0.30%)

WHR

Whirlpool

$148.30

0.085 (0.06%)

AMTD

TD Ameritrade

$52.41

0.82 (1.59%)

ACAD

Acadia

$25.97

0.28 (1.09%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Jul

  • 22

    Jul

  • 22

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 23

    Jul

  • 25

    Jul

  • 31

    Jul

  • 31

    Jul

  • 03

    Aug

  • 06

    Aug

  • 20

    Aug

  • 21

    Aug

  • 26

    Sep

  • 27

    Sep

SNAP

Snap

$14.14

0.12 (0.86%)

18:35
07/22/19
07/22
18:35
07/22/19
18:35
Upgrade
Snap rating change at Stifel »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

SMBC

Southern Missouri Bancorp

$31.95

-0.3 (-0.93%)

18:33
07/22/19
07/22
18:33
07/22/19
18:33
Earnings
Southern Missouri Bancorp sees Q4 EPS 81c, consensus 77c »

Southern Missouri…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

SSRM

SSR Mining

$15.80

-0.06 (-0.38%)

18:32
07/22/19
07/22
18:32
07/22/19
18:32
Hot Stocks
SSR Mining to acquire remaining 25% interest in Puna Operations »

SSR Mining announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Aug

SNAP

Snap

$14.14

0.12 (0.86%)

18:23
07/22/19
07/22
18:23
07/22/19
18:23
Upgrade
Snap rating change at Stifel »

Snap upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 03

    Aug

HD

Home Depot

$211.23

-1.79 (-0.84%)

18:22
07/22/19
07/22
18:22
07/22/19
18:22
Hot Stocks
Home Depot CFO: The company is in great hands »

In an interview on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Aug

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:21
07/22/19
07/22
18:21
07/22/19
18:21
Hot Stocks
Breaking Hot Stocks news story on AutoNation »

AutoNation down 2.6%…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

AN

AutoNation

$42.01

-0.045 (-0.11%)

18:17
07/22/19
07/22
18:17
07/22/19
18:17
Earnings
AutoNation reports Q2 cont ops EPS $1.12, consensus $1.06 »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 13

    Nov

CR

Crane

$86.50

0.99 (1.16%)

18:15
07/22/19
07/22
18:15
07/22/19
18:15
Earnings
Crane backs FY19 adjusted EPS view of $6.25-$6.45, consensus $6.41 »

Backs FY19 revenue view…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

CR

Crane

$86.50

0.99 (1.16%)

18:14
07/22/19
07/22
18:14
07/22/19
18:14
Earnings
Crane Co. reports Q2 EPS ex-items $1.58, consensus $1.56 »

Reports Q2 revenue $842M,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 09

    Sep

  • 09

    Sep

AN

AutoNation

$42.01

-0.045 (-0.11%)

, GOOG

Alphabet

$1,138.09

8.09 (0.72%)

18:11
07/22/19
07/22
18:11
07/22/19
18:11
Hot Stocks
AutoNation names Cheryl Miller CEO »

AutoNation (AN) announced…

AN

AutoNation

$42.01

-0.045 (-0.11%)

GOOG

Alphabet

$1,138.09

8.09 (0.72%)

GOOGL

Alphabet Class A

$1,139.52

7.85 (0.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 25

    Jul

  • 25

    Jul

  • 03

    Aug

  • 08

    Aug

  • 27

    Oct

  • 13

    Nov

STLD

Steel Dynamics

$31.55

0.09 (0.29%)

18:04
07/22/19
07/22
18:04
07/22/19
18:04
Hot Stocks
Steel Dynamics reports Q2 operating income $295M, down 6% from Q1 »

Q2 average external…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Jul

  • 06

    Aug

FBMS

First Bancshares

$29.74

-0.105 (-0.35%)

18:03
07/22/19
07/22
18:03
07/22/19
18:03
Hot Stocks
First Bancshares announces agreement to acquires First Florida Bancorp »

The First Bancshares,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Sep

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.